[ad_1]
The US Food and Drug Administration has approved two cancer treatments, Vitrakvi and Xospata, several weeks after the review.
Vitravki is a treatment for adults and children with certain cancers with specific genetic characteristics.
The Food and Drug Administration said in a statement that "Vitravki" is the second drug of its kind that targets cancer on a genetic basis, regardless of its origin in the patient's body.
Vitravki will be used to treat an advanced type of cancer containing a genetic fusion called NTRK, which helps uncontrolled cell growth.
"This type of drug development program, implemented in patients with different types of cancer but involved in a specific genetic mutation, was impossible ten years ago because we did not know much about genetic mutations in cancer. "said Scott Gottlieb, US commissioner for the Food and Drug Administration. .
Last year, the administration approved for the first time a drug for certain cancers with specific genetic imprints, regardless of their origin in the body, and allowed it to be used in the treatment of several types of cancer, including including advanced melanoma.
Source link
